Originally Posted by
Southern Lad
Given the Share Purchase Plan isn’t underwritten and assuming the $130m placement was in fact fully subscribed without the underwriter applying for shares to avoid the optics of there being a shortfall, what role does Jarden have tomorrow other than trying to keep its clients who did participate in the placement happy?
Without having the SPP underwritten, HGH runs the risk of raising less than $70m if the share price falls to $1.80 or below. Are you suggesting the HGH will be paying Jarden to underpin the share price until the SPP closes?